Pain management in multiple myeloma

References

• Niscola P, Arcuri E, Giovannini M et al. Pain syndromes in haematological malignancies: an overview. Hematol. J.5(4), 293–303 (2004).
   PubMedGoogle Scholar
• Poulos AR, Gertz MA, Pankratz VS, Post-White J. Pain, mood disturbance, and quality of life in patients with multiple myeloma. Oncol. Nurs. Forum28(7), 1163–1171 (2001).
   PubMedGoogle Scholar
• Lennert H. Pain therapy in multiple myeloma – clinical experience from an observational study. The Pain Clinic18(2)6, 131–136 (2006).
   Web of Science ®Google Scholar
• Smith A, Wisloff F, Samson D. UK Myeloma Forum; Nordic Myeloma Study Group; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br. J. Haematol.132(4), 410–451 (2006).
   PubMed Web of Science ®Google Scholar
• Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin. Proc.50(1), 29–40 (1975).
   PubMed Web of Science ®Google Scholar
• Zappasodi P, Corso A, Klersy C et al. Changes in multiple myeloma epidemiology in the last thirty years: a single centre experience. Eur. J. Cancer42(3), 396–402 (2006).
   PubMed Web of Science ®Google Scholar
• Niscola P, Romani C, Cartoni C et al. Epidemiology of pain in hospital haematological setting: an Italian survey. Leuk. Res.32(1), 197–198 (2008).
   PubMed Web of Science ®Google Scholar
• Niscola P, Cartoni C, Romani C et al. Epidemiology, features and outcome of pain in patients with advanced hematological malignancies followed in a home care program: an Italian survey. Ann. Hematol.86(9), 671–676 (2007).
   PubMed Web of Science ®Google Scholar
• Roodman GD. Pathogenesis of myeloma bone disease. Leukemia23(3), 435–441 (2009).
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle RA. Neurological aspects of multiple myeloma and related disorders. Best Pract. Res. Clin. Haematol.18(4), 673–688 (2005).
   PubMed Web of Science ®Google Scholar
• Silberman J, Lonial S. Review of peripheral neuropathy in plasma cell disorders. Hematol. Oncol.26(2), 55–65 (2008).
   PubMed Web of Science ®Google Scholar
• Suzuki M, Ohashi K, Sakamaki H. Immunoglobulin D plasmacytoma carrying aberrant expression of CD33 associated with aggressive visceral involvement. Haematologica86(8), 895 (2001).
   PubMedGoogle Scholar
• Niscola P, Scaramucci L, Morabito F et al. Pleural effusion by malignant plasma cells in advanced multiple myeloma: report of three cases with a brief overview. Haematologica7(4), 516–519 (2004).
   Google Scholar
• Ochiai N, Shimazaki C, Okano A et al. Meningeal relapse after double peripheral blood stem cell transplantation in IgD myeloma. Leuk. Lymphoma43(3), 641–643 (2002).
   PubMed Web of Science ®Google Scholar
• Desikan R, Barlogie B, Sethi R et al. Infection 2004 – an underappreciated cause of bone pain in multiple myeloma. Br. J. Haematol.120(6), 1047–1050 (2003).
   PubMedGoogle Scholar
• Niscola P, Perrotti AP, del Poeta G et al. Case reports: zoster pain in haematological malignancies: effective pain relief with oxycodone in patients unresponsive to other analgesic measures. Herpes14(2), 45–47 (2007).
   PubMedGoogle Scholar
• Leena M, Ville V, Veli-Jukka A. Visceral varicella zoster virus infection after stem cell transplantation: a possible cause of severe abdominal pain. Scand J. Gastroenterol.41(2), 242–244 (2006).
   PubMed Web of Science ®Google Scholar
• Coutaux A, Salomon L, Rosenheim M et al. Care related pain in hospitalized patients: a cross-sectional study. Eur. J. Pain12(1), 3–8 (2008).
   PubMed Web of Science ®Google Scholar
• Niscola P, Romani C, Cupelli L et al. Mucositis in patients with hematologic malignancies: an overview. Haematologica92(2), 222–231 (2007).
   PubMed Web of Science ®Google Scholar
• Niscola P, Romani C, Scaramucci L et al. Pain syndromes in the setting of haematopoietic stem cell transplantation for haematological malignancies. Bone Marrow Transplant.41(9), 757–764 (2008).
   PubMed Web of Science ®Google Scholar
• Smith LC, Bertolotti P, Curran K, Jenkins B. IMF Nurse Leadership Board. Gastrointestinal side effects associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF nurse leadership board. Clin. J. Oncol. Nurs.12(3 Suppl.), 37–52 (2008).
   PubMedGoogle Scholar
• Siniscalchi A, Tendas A, Ales M et al. Bortezomib-related colon mucositis in a multiple myeloma patient. Support Care Cancer17(4), 325–327 (2009).
   PubMed Web of Science ®Google Scholar
• Srinivasan D, Shetty S, Ashworth D, Grew N, Millar B. Orofacial pain – a presenting symptom of bisphosphonate associated osteonecrosis of the jaws. Br. Dent. J.203(2), 91–92 (2007).
   PubMed Web of Science ®Google Scholar
• Badros A, Terpos E, Katodritou E et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J. Clin. Oncol.26(36), 5904–5909(2008).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Bamia C et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann. Oncol.20(1), 117–120 (2009).
   PubMed Web of Science ®Google Scholar
• Vahtsevanos K, Kyrgidis A, Verrou E et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J. Clin. Oncol.27(32), 5356–5362 (2009).
   PubMed Web of Science ®Google Scholar
• Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol.44(9), 857–869 (2008).
   PubMed Web of Science ®Google Scholar
• Treister NS, Richardson P, Schlossman R, Miller K, Woo SB. Painful tongue ulcerations in patients with bisphosphonate-associated osteonecrosis of the jaws. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.105(6), E1–E4 (2008).
   PubMedGoogle Scholar
• Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J. Clin. Oncol.24(27), 4507–4514 (2006).
   PubMed Web of Science ®Google Scholar
• Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J. Peripher. Nerv. Syst.13(4), 275–282 (2008).
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J. Support. Oncol.1(3), 194–205 (2003).
   PubMedGoogle Scholar
• Richardson PG, Sonneveld P, Schuster MW et al. Assessment of proteasome inhibition for extending remissions (APEX) investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med.352(24), 2487–2498 (2005).
   PubMed Web of Science ®Google Scholar
• Cata JP, Weng HR, Burton AW, Villareal H, Giralt S, Dougherty PM. Quantitative sensory findings in patients with bortezomib-induced pain. J. Pain8(4), 296–306 (2007).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Briemberg H, Jagannath S et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J. Clin. Oncol.24(19), 3113–3120 (2006).
   PubMed Web of Science ®Google Scholar
• El-Cheikh J, Stoppa AM, Bouabdallah R et al. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma. Clin. Lymphoma Myeloma8(3), 146–152 (2008).
   PubMedGoogle Scholar
• Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood112(5), 1593–1599 (2008).
   PubMed Web of Science ®Google Scholar
• Sioka C, Kyritsis AP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother. Pharmacol.63(5), 761–767 (2009).
   PubMed Web of Science ®Google Scholar
• Ravaglia S, Corso A, Piccolo G et al. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin. Neurophysiol.119(11), 2507–2512 (2008).
   PubMed Web of Science ®Google Scholar
• Woolf CJ. American College of Physicians; American Physiological Society. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann. Intern. Med.140(6), 441–451 (2004).
   PubMed Web of Science ®Google Scholar
• Mercadante S, Radbruch L, Caraceni A et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European association for palliative care. Cancer94(3), 832–839 (2002).
   PubMed Web of Science ®Google Scholar
• Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J. Pain10(9), 895–926 (2009).
   PubMed Web of Science ®Google Scholar
• Davis MP, Walsh D. Cancer pain: how to measure the fifth vital sign. Cleve. Clin. J. Med.71(8), 625–632 (2004).
   PubMed Web of Science ®Google Scholar
• Breyer RJ 3rd, Mulligan ME, Smith SE, Line BR, Badros AZ. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiol.35(9), 632–640 (2006).
   PubMed Web of Science ®Google Scholar
• Dinter DJ, Neff WK, Klaus J et al. Comparison of whole-body MR imaging and conventional x-ray examination in patients with multiple myeloma and implications for therapy. Ann. Hematol.88(5), 457–464 (2009).
   PubMed Web of Science ®Google Scholar
• Delorme S, Baur-Melnyk A. Imaging in multiple myeloma. Eur. J. Radiol.70(3), 401–408 (2009).
   PubMedGoogle Scholar
• Kyle RA, Yee GC, Somerfield MR et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J. Clin. Oncol.25(17), 2464–2472 (2007).
   PubMed Web of Science ®Google Scholar
• Musto P, Petrucci MT, Bringhen S et al. A multicenter randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Eur. J. Radiol.113(7), 1588–1595 (2008).
   Google Scholar
• Keefe DM, Schubert MM, Elting LS et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer109(5), 820–831 (2007).
   PubMed Web of Science ®Google Scholar
• Lilleby K, Garcia P, Gooley T et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant.37(11), 1031–1035 (2006).
   PubMed Web of Science ®Google Scholar
• Spielberger R, Stiff P, Bensinger W et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N. Engl. J. Med.351(25), 2590–2598 (2004).
   PubMed Web of Science ®Google Scholar
• Tariman JD, Love G, McCullagh E, Sandifer S; IMF Nurse Leadership Board. Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin. J. Oncol. Nurs.12(3 Suppl.), 29–36 (2008).
   PubMed Web of Science ®Google Scholar
• Stillman M, Cata JP. Management of chemotherapy-induced peripheral neuropathy. Curr. Pain Headache Rep.10(4), 279–287 (2006).
   PubMedGoogle Scholar
• Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur. J. Cancer44(11), 1507–1515 (2008).
   PubMed Web of Science ®Google Scholar
• Niscola P, Scaramucci L, Romani C et al. Opioids in pain management of blood-related malignancies. Ann. Hematol.85(8), 489–501 (2006).
   PubMed Web of Science ®Google Scholar
• Mose S, Pfitzner D, Rahn A, Nierhoff C, Schiemann M, Bottcher HD. Role of radiotherapy in the treatment of multiple myeloma. Strahlenther Onkol.176(11), 506–512 (2000).
   PubMed Web of Science ®Google Scholar
• Sze WM, Shelley MD, Held I, Wilt TJ, Mason MD. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy – a systematic review of randomised trials. Clin. Oncol. (R. Coll. Radiol.)15(6), 345–352 (2003).
   PubMed Web of Science ®Google Scholar
• van den Hout WB, van der Linden YM, Steenland E et al. Single versus multiple-fraction radiotherapy in patients with painful bone metastases: cost–utility analysis based on a randomized trial. J. Natl Cancer Inst.95(3), 222–229 (2003).
   PubMedGoogle Scholar
• Rades D, Hoskin PJ, Stalpers LJ et al. Short-course radiotherapy is not optimal for spinal cord compression due to myeloma. Int. J. Radiat. Oncol. Biol. Phys.64(5), 1452–1457 (2006).
   PubMedGoogle Scholar
• Munk PL, Rashid F, Heran MK et al. Combined cementoplasty and radiofrequency ablation in the treatment of painful neoplastic lesions of bone. J. Vasc. Interv. Radiol.20(7), 903–911 (2009).
   PubMed Web of Science ®Google Scholar
• Ripamonti C, Fagnoni E, Campa T, Seregni E, Maccauro M, Bombardieri E. Incident pain and analgesic consumption decrease after samarium infusion: a pilot study. Support Care Cancer15(3), 339–342 (2007).
   PubMed Web of Science ®Google Scholar
• Abruzzese E, Iuliano F, Trawinska MM, Di Maio M. 153Sm: its use in multiple myeloma and report of a clinical experience. Expert Opin. Investig. Drugs17(9), 1379–1387 (2008).
   PubMed Web of Science ®Google Scholar
• Buchbinder R, Osborne RH, Ebeling PR et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N. Engl. J. Med.361(6), 557–568 (2009).
   PubMed Web of Science ®Google Scholar
• Masala S, Anselmetti GC, Marcia S, Massari F, Manca A, Simonetti G. Percutaneous vertebroplasty in multiple myeloma vertebral involvement. J. Spinal Disord. Tech.21(5), 344–348 (2008).
   PubMed Web of Science ®Google Scholar
• Astolfi S, Scaramuzzo L, Logroscino CA. A minimally invasive surgical treatment possibility of osteolytic vertebral collapse in multiple myeloma. Eur. Spine J.18(Suppl. 1), 115–121 (2009).
   PubMedGoogle Scholar
• Tran Thang NN, Abdo G, Martin JB, Seium-Neberay Y et al. Percutaneous cementoplasty in multiple myeloma: a valuable adjunct for pain control and ambulation maintenance. Support Care Cancer16(8), 891–896 (2008).
   PubMedGoogle Scholar
• World Health Organization. Cancer Pain Relief. World Health Organization, Geneva, Switzerland (1986).
   Google Scholar
• Jensen TS, Madsen CS, Finnerup NB. Pharmacology and treatment of neuropathic pains. Curr. Opin. Neurol.22(5), 467–474 (2009).
   PubMed Web of Science ®Google Scholar
• Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. BMJ326, 748–750 (2003).
   PubMed Web of Science ®Google Scholar
• Cavazzini F. The combination acetominophen/tramadol in hematological daily practice. Minerva Med.99(6), 631–641 (2008).
   PubMedGoogle Scholar
• Cartoni C, Brunetti GA, Niscola P, Alfieri PL, Delia GM, Foà R. Pain management of bortezomib-induced neuropathy with oral controlled-release oxycodone. Haematologica94(Suppl. 2), 49 (2009).
   Google Scholar
• Casuccio A, Mercadante S, Fulfaro F. Treatment strategies for cancer patients with breakthrough pain. Expert Opin. Pharmacother.10(6), 947–953 (2009).
   PubMed Web of Science ®Google Scholar
• Stanos SP. Topical agents for the management of musculoskeletal pain. J. Pain Symptom Manage.33(3), 342–355 (2007).
   PubMed Web of Science ®Google Scholar
• Dajani EZ, Islam K. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. J. Physiol. Pharmacol.59(Suppl 2), 117–133 (2008).
   PubMedGoogle Scholar
• Inturrisi CE. Clinical pharmacology of opioids for pain. Clin. J. Pain18(4 Suppl.), S3–S13 (2002).
   PubMedGoogle Scholar
• Hanks GW, de Conno F, Cherny N et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations Expert Working Group of the Research Network of the European Association for Palliative Care. Br. J. Cancer84, 587–593 (2001).
   PubMed Web of Science ®Google Scholar
• Swarm R, Anghelescu DL, Benedetti C et al. National comprehensive cancer network (NCCN). Adult cancer pain. J. Natl Compr. Canc. Netw.5(8), 726–751 (2007).
   PubMedGoogle Scholar
• Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin. Pharmacokinet.43(13), 879–923 (2004).
   PubMed Web of Science ®Google Scholar
• Mercadante S. Methadone in cancer pain. Eur. J. Pain1(2), 77–83 (1997).
   PubMedGoogle Scholar
• Kress HG, Von der Laage D, Hoerauf KH et al. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared with standard opioid treatment in cancer pain. J. Pain Symptom Manage.36(3), 268–279 (2008).
   PubMed Web of Science ®Google Scholar
• Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J. Support. Oncol.5(7), 327–334 (2007).
   PubMedGoogle Scholar
• Pergolizzi JV, Mercadante S, Echaburu AV et al. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr. Med. Res. Opin.25(6), 1517–1528 (2009).
   PubMed Web of Science ®Google Scholar
• Mercadante S, Casuccio A, Tirelli W, Giarratano A. Equipotent doses to switch from high doses of opioids to transdermal buprenorphine. Support Care Cancer17(6), 715–718 (2009).
   PubMedGoogle Scholar
• Cherny N, Ripamonti C, Pereira J et al. Expert Working Group of the European Association of Palliative Care Network. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J. Clin. Oncol.19(9), 2542–2554(2001).
   PubMed Web of Science ®Google Scholar
• O’Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am. J. Med.122(10 Suppl.), S22–S32 (2009).
   PubMed Web of Science ®Google Scholar
• Jensen TS, Madsen CS, Finnerup NB. Pharmacology and treatment of neuropathic pains. Curr. Opin. Neurol.22(5), 467–474 (2009).
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Otto M, Jensen TS, Sindrup SH. An evidence-based algorithm for the treatment of neuropathic pain. MedGenMed9(2), 36 (2007).
   PubMedGoogle Scholar
• Mercadante S, Arcuri E. Opioids and renal function. J. Pain5(1), 2–19 (2004).
   PubMed Web of Science ®Google Scholar
• Niscola P, Scaramucci L, Vischini G et al. The use of major analgesics in patients with renal dysfunction. Curr. Drug Targets (2010) (In press).
   Google Scholar
• Cassileth B, Trevisan C, Gubili J. Complementary therapies for cancer pain. Curr. Pain Headache Rep.11(4), 265–269 (2007).
   PubMedGoogle Scholar
• Jones LW, Courneya KS, Vallance JK et al. Understanding the determinants of exercise intentions in multiple myeloma cancer survivors: an application of the theory of planned behavior. Cancer Nurs.29(3), 167–175 (2006).
   PubMed Web of Science ®Google Scholar
• Stanos SP, McLean J, Rader L. Physical medicine rehabilitation approach to pain. Med. Clin. North Am.91(1), 57–95 (2007).
   PubMed Web of Science ®Google Scholar
• Falco P, Cavallo F, Larocca A et al. Lenalidomide and its role in the management of multiple myeloma. Expert Rev. Anticancer. Ther.8(6), 865–874 (2008).
   PubMed Web of Science ®Google Scholar
• Laubach JP, Mitsiades CS, Mahindra A et al. Novel therapies in the treatment of multiple myeloma. J. Natl Compr. Canc. Netw.7(9), 947–960 (2009).
   PubMed Web of Science ®Google Scholar
• Roodman GD. Novel targets for myeloma bone disease. Expert Opin. Ther. Targets12(11), 1377–1387 (2008).
   PubMed Web of Science ®Google Scholar